Artelo Biosciences, Inc.
ARTLAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | downgrade | Buy →Hold | Nov 19, 2025 |
| D. Boral Capital | downgrade | Buy →Hold | Sep 8, 2025 |
| D. Boral Capital | maintain | Buy | Aug 26, 2025 |
| D. Boral Capital | maintain | Buy | Aug 18, 2025 |
| D. Boral Capital | maintain | Buy | Aug 6, 2025 |
| D. Boral Capital | maintain | Buy | Aug 4, 2025 |
| D. Boral Capital | upgrade | Hold →Buy | Jul 8, 2025 |
| D. Boral Capital | downgrade | Buy →Hold | Jun 11, 2025 |
| D. Boral Capital | maintain | Buy | Jun 6, 2025 |
| D. Boral Capital | maintain | Buy | Apr 28, 2025 |
| D. Boral Capital | maintain | Buy | Apr 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 4, 2025 |
| D. Boral Capital | maintain | Buy | Mar 3, 2025 |
| D. Boral Capital | maintain | Buy | Feb 27, 2025 |
| D. Boral Capital | maintain | Buy | Jan 14, 2025 |
| D. Boral Capital | maintain | Buy | Dec 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2023 |
| Ladenburg Thalmann | maintain | Buy | Apr 3, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 3, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2022 |
Earnings History
Next report: Nov 17, 2026 · EPS est. $-7.02| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-8.01 | $-6.48 | — | — |
| May 14, 2026 | $-4.00 | $-0.78 | — | — |
| Feb 24, 2026 | $-6.66 | $-4.71 | — | — |
| Nov 12, 2025 | $-11.91 | $-2.46 | — | — |
| Aug 12, 2025 | $-16.83 | $-12.57 | — | — |
| May 13, 2025 | $-12.96 | $-2.40 | — | — |
| Mar 24, 2025 | $-21.06 | $-6.66 | — | — |
| Nov 12, 2024 | $-3.15 | $-4.14 | — | — |
News
Nonclinical studies demonstrated reductions in two key measures of neuropathic pain Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple cancer-related symptoms SOLANA BEACH, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermato…
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world's largest gathering of pain professionals
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 46,160 shares, a growth of 104.7% from the September 15th total of 22,550 shares. Based on an average trading volume of 2,494,370 shares, the days-to-cover ratio
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 22,550 shares, a decrease of 37.2% from the August 31st total of 35,918 shares. Based on an average trading volume of 45,211 shares, the short-interest ratio
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks
Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ®
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 85,320 shares, a decline of 36.9% from the July 30th total of 135,122 shares. Currently, 1.9% of the shares of the company are sold short. Based
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company's patent application covering the intended commercial for…
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issue…
SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the second quarter ended June 30, 2026.